Abstract:Abstract Abstract 2310 Acute GVHD is a proinflammatory process mediated in part by mature donor T cells present in the stem cell or marrow inoculums that are polarized toward a Th1 phenotype and recognize minor or major histocompatibility disparities between the donor and host. A large amount of data has clearly shown that a newly identified subset of interleukin (IL)-17-producing CD4 T lymphocytes, named TH-17 cells, play a crucial role in triggering inflammation and tissue injury in various autoimmune diseases. The role of TH17 cells in acute GVHD had been controversial in recent mice and human transplantation. The aim of this study was to investigate the effects of IL17-producing T cells, including Th17 and Tc17 cells, on GVHD in patients receiving granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell (PBPCs) and G-CSF-primed bone marrow (GBM) transplantation. Forty-one patients were analyzed according to the Th17 and Tc17 cell content in allograft in relation to aGVHD. Furthermore, ten patients with acute GVHD onset were monitored for the presence of Th17 cells by flow cytometry in the peripheral blood. Patients who subsequently developed aGVHD have greater proportions and doses of Th17 and Tc17 cells in GBM and PBPCs allograft infused into the patients (p=0.049 and 0.029 for Th17 in GBM; p=0.078 and p=0.033 for Tc17 in GBM; p=0.103 and 0.008 for Th17 in PBPCs; p=0.007 and 0.001 for Tc17 cells in PBPCs). At the same time, there were also significantly higher proportions and doses of Th1 and Tc1 cells in GBM and PBPCs allograft in patients with aGVHD compared with those levels in patients without aGVHD. Acute GVHD occurred 20 patients occurred, among which were 2 patients with gastrointestinal GVHD, 4 patients with skin plus gastrointestinal GVHD and the 14 others with simple skin GVHD. When we further compared patients according to the aGVHD target organ, we also found the significant association between dose of IL17 producing T cells (Th17 and Tc17) and the occurrence of simple skin GVHD. Cox regression models demonstrated that dose of Th17 in GBM (RR 1.095, CI 1.032– 1.162, P=0.003), dose of Tc17 in PBPCs (RR 1.063, CI 1.017– 1.112, P=0.008) and the number of HLA locus mismatch (RR 1.84, CI 1.18– 2.87, P=0.008) emerged as the independent factors influencing the occurrence of aGVHD. Patients receiving a higher dose of Th17 cells in GBM allograft (>8.5×104/kg, p=0.005), and Tc17 cells in PBPCs (>16.8×104/kg, p=0.001) exhibited a higher incidence of aGVHD. An increased Th17 population (up to 4.99% of CD4 T lymphocytes) was observed in patients with acute GVHD onset. In contrast, the percentage of Th17 cells drastically decreased in GVHD patients when they were treated to achieve partial and complete remission (p=0.013 and p=0.008, respectively). All percentages of Th17 and Tc17 were significantly reduced after G-CSF in vivo application. Our results suggest IL-17 producing T cells contribute to mediate aGVHD. Furthermore, G-CSF in vivo application helps to reduce the occurrence of aGVHD through reducing the secretion of IL17 in T cells. Disclosures: No relevant conflicts of interest to declare.

Kinetics of interferon-gamma secretion and its regulatory factors in the early phase of acute graft-versus-host disease

INTERLEUKIN-18 (IL-18) And IL-18 binding protein (IL-18bp) And acute graft versus host disease (Gvhd)

IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma.

Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation

Differential upregulation of interleukin-18 receptor alpha chain between CD4+ and CD8+ T cells during acute graft-versus-host disease in mice

Interleukin-18 Binding Protein in Acute Graft versus Host Disease and Engraftment Following Allogeneic Peripheral Blood Stem Cell Transplants

The Identification and Characteristics of Il-22-Producing T Cells in Acute Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation

Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation

IL12 and IFNγ secretion by donor mononuclear cells in response to host antigens may predict acute GVHD after HSCT

Increased expression of T cell immune response cDNA 7 in patients with acute graft-versus-host disease

Cytokines are early diagnostic biomarkers of graft-versus-host disease in liver recipients

Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis

Cytokine Profiles in Various Graft-Versus-Host Disease Target Organs following Hematopoietic Stem Cell Transplantation

Role of interleukin-18 in acute graft-vs-host disease

Pathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular Effectors

Increased expression of IL-18 in cutaneous graft-versus-host disease

IL-12 is a central mediator of acute graft-versus-host disease in mice.

[Experimental Study of Tripterygium Hypoglaucum (level) Hutch on Preventing Acute Graft-Versus-host Disease in Bone Marrow Transplantation Mice].

[Role of interleukin-18 in pathogenesis of acute graft-versus-host disease]

IL-17-Producing T Cells Contribute to Mediate Acutegraft-Versus-Disease in Patients Undergoing Unmanipulated Blood and MarrowTransplantation

Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease